Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT01010373 Suspended - Clinical trials for Acute Myeloid Leukemia

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Start date: January 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether addition of AS101 to the standard chemotherapy regimen is effective in the treatment of newly diagnosed elderly (≥60) AML patients and AML transformed myelodysplastic syndrome (MDS) patients.

NCT ID: NCT00991744 Suspended - Clinical trials for Acute Lymphoblastic Leukemia

Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)

Start date: January 2009
Phase: Phase 3
Study type: Interventional

- Replacement of intrathecal Triple (methotrexate, cytarabine, prednisolone) with intrathecal liposomal cytarabine and prednisolone during maintenance therapy will decrease the CNS relapse rate in high-risk ALL patients. - Both acute and long-term toxicity are equal in both treatment arms.

NCT ID: NCT00935090 Suspended - Lymphoma Clinical Trials

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Start date: September 2009
Phase: N/A
Study type: Interventional

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

NCT ID: NCT00587457 Suspended - Leukemia, Lymphoma Clinical Trials

A Phase I,Multicenter, Dose Escalation Study of CAT-8015 in Patients With Chronic Leukemia

Start date: March 2007
Phase: Phase 1
Study type: Interventional

To demonstrate the safety of CAT-8015 at MTD dose.

NCT ID: NCT00329498 Suspended - Clinical trials for Acute Myeloid Leukemia

L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes

Start date: May 1998
Phase: Phase 2
Study type: Interventional

To document therapeutic gain achieved by cyclic application of L-ascorbic acid (LAA) supplementation and depletion, while confirming safety and avoidance of clinically significant scurvy, in chemorefractory patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

NCT ID: NCT00077493 Suspended - Lymphoma Clinical Trials

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Start date: January 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma. PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating young patients with relapsed or refractory acute lymphoblastic leukemia or non-Hodgkin's lymphoma.